Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Benign Prostatic Hypertrophy | Research

Improvement of urinary tract symptoms and quality of life in benign prostate hyperplasia patients associated with consumption of a newly developed whole tomato-based food supplement: a phase II prospective, randomized double-blinded, placebo-controlled study

Authors: Luigi Cormio, Beppe Calò, Ugo Falagario, Manuela Iezzi, Alessia Lamolinara, Paola Vitaglione, Giovanni Silecchia, Giuseppe Carrieri, Vincenzo Fogliano, Stefano Iacobelli, Pier Giorgio Natali, Mauro Piantelli

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

Benign prostatic hyperplasia (BPH) is the most common urologic disease among elderly men. The diagnosis of BPH is usually driven by lower urinary tract symptoms (LUTS) that can significantly affect patients’ quality of life. This phase II prospective, randomized double-blinded, placebo-controlled study aimed to determine the efficacy and safety of a novel whole tomato-based food supplement on LUTS of patients diagnosed with BPH.

Methods

Forty consecutive patients with histologically proved BPH were randomized 1:1 to receive daily for 2 months a sachet (5 g) of a newly developed whole tomato food supplement (WTFS) (treatment = Group A) or placebo (Group B). Patients were asked to fill the International Prostatic Symptom Score (IPSS) questionnaire before and after treatment.

Results

All but 1 patient in Group B successfully completed the scheduled regimen. No side effects were recorded. Unlike placebo, treatment significantly reduced (P < 0.0002) LUTS since mean IPSS decreased from 9.05 ± 1.15 to 7.15 ± 1.04 (paired t-test, two-tailed P-value < 0.001), and improved life quality (P < 0.0001). A trend toward a reduction of total PSA levels was observed in WTFS treated patients (8.98 ng/mL ± 1.52 vs 6.95 ± 0.76, P = 0.065), with changes being statistically significant only in the subgroup of patients with baseline levels above 10 ng/mL (18.5 ng/mL ± 2.7 vs 10.3 ± 2.1, P = 0.009).

Conclusions

The new WTFS may represent a valid option for the treatment of symptomatic BPH patients. Unlike pharmacological treatments, the supplement is side effects free and highly accepted among patients.
Literature
1.
go back to reference McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(5 Suppl):S122–8.PubMed McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(5 Suppl):S122–8.PubMed
2.
go back to reference Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101(Suppl3):17–21.PubMedCrossRef Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101(Suppl3):17–21.PubMedCrossRef
3.
go back to reference McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long- term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.PubMedCrossRef McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long- term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.PubMedCrossRef
4.
go back to reference Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13(3):147–50.PubMedPubMedCentral Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13(3):147–50.PubMedPubMedCentral
5.
go back to reference Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep. 2014;15(12):463–9.PubMedCrossRef Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep. 2014;15(12):463–9.PubMedCrossRef
6.
go back to reference Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int. 2013;111(2):304–11.PubMedCrossRef Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int. 2013;111(2):304–11.PubMedCrossRef
7.
go back to reference Fowke JH, Koyama T, Fadare O, Clark PE. Does inflammation mediate the obesity and BPH relationship? An epidemiologic analysis of body composition and inflammatory markers in blood, urine, and prostate tissue, and the relationship with prostate enlargement and lower urinary tract. PLoS ONE. 2016;11(6):e0156918.PubMedPubMedCentralCrossRef Fowke JH, Koyama T, Fadare O, Clark PE. Does inflammation mediate the obesity and BPH relationship? An epidemiologic analysis of body composition and inflammatory markers in blood, urine, and prostate tissue, and the relationship with prostate enlargement and lower urinary tract. PLoS ONE. 2016;11(6):e0156918.PubMedPubMedCentralCrossRef
8.
go back to reference Pagano E, Laudato M, Griffo M, Capasso R. Phytotherapy of benign prostatic hyperplasia. A minirewiev Phytother Res. 2014;28(7):949–55.PubMedCrossRef Pagano E, Laudato M, Griffo M, Capasso R. Phytotherapy of benign prostatic hyperplasia. A minirewiev Phytother Res. 2014;28(7):949–55.PubMedCrossRef
9.
go back to reference Mohri S, Takahashi H, Sakai M, Takahashi S, Waki N, Alzawa K, et al. Wide-range screening of anti-inflammatory compounds in tomato using LC-MS and elucidating the mechanism of their functions. PLoS ONE. 2018;12(13):e0191203.CrossRef Mohri S, Takahashi H, Sakai M, Takahashi S, Waki N, Alzawa K, et al. Wide-range screening of anti-inflammatory compounds in tomato using LC-MS and elucidating the mechanism of their functions. PLoS ONE. 2018;12(13):e0191203.CrossRef
11.
go back to reference Ghavipour M, Saedisomeolia A, Dialali M, Sotoudeh G, Eshraghyan MR, Moghadam AM, et al. Tomato juice consumption reduces systemic inflammation in overweight and obese females. Br J Nutr. 2013;109(11):2031–5.PubMedCrossRef Ghavipour M, Saedisomeolia A, Dialali M, Sotoudeh G, Eshraghyan MR, Moghadam AM, et al. Tomato juice consumption reduces systemic inflammation in overweight and obese females. Br J Nutr. 2013;109(11):2031–5.PubMedCrossRef
12.
go back to reference Li YF, Chang YY, Huang HC, Wu YC, Yang MD, Chao P-M. Tomato juice supplementation in young women reduces inflammatory adipokine levels independently of body fat reduction. Nutrition. 2016;31(5):691–6.CrossRef Li YF, Chang YY, Huang HC, Wu YC, Yang MD, Chao P-M. Tomato juice supplementation in young women reduces inflammatory adipokine levels independently of body fat reduction. Nutrition. 2016;31(5):691–6.CrossRef
13.
go back to reference Vitaglione P, Fogliano V, Stingo S, Scalfi L, Caporaso N, Morisco F. Development of a tomato-based food for special medical purposes as therapy adjuvant for patients with HCV infection. Eur J Clin Nutr. 2007;61(7):906–15.PubMedCrossRef Vitaglione P, Fogliano V, Stingo S, Scalfi L, Caporaso N, Morisco F. Development of a tomato-based food for special medical purposes as therapy adjuvant for patients with HCV infection. Eur J Clin Nutr. 2007;61(7):906–15.PubMedCrossRef
14.
go back to reference Pannellini T, Iezzi M, Liberatore M, Sabatini F, Iacobelli S, Rossi C, et al. A dietary tomato supplement prevents prostate cancer in TRAMP mice. Cancer Prev Res. 2010;3(10):1284–91.CrossRef Pannellini T, Iezzi M, Liberatore M, Sabatini F, Iacobelli S, Rossi C, et al. A dietary tomato supplement prevents prostate cancer in TRAMP mice. Cancer Prev Res. 2010;3(10):1284–91.CrossRef
15.
go back to reference Conlon LE, Wallig MA, Erdman JW Jr. Low-lycopene containing tomato powder diet does not protect against prostate cancer in TRAMP mice. Nutr Res. 2015;35(10):882–90.PubMedCrossRef Conlon LE, Wallig MA, Erdman JW Jr. Low-lycopene containing tomato powder diet does not protect against prostate cancer in TRAMP mice. Nutr Res. 2015;35(10):882–90.PubMedCrossRef
16.
go back to reference Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW Jr, Clinton SK. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Nat Cancer Inst. 2003;95(21):1578–86.PubMedCrossRef Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW Jr, Clinton SK. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Nat Cancer Inst. 2003;95(21):1578–86.PubMedCrossRef
17.
go back to reference Canene-Adams K, Lindshield BL, Wang S, Jeffery EH, Clinton SK, Erdman JW Jr. Combinations of tomato and broccoli enhance antitumor activity in Dunning R3327-H prostate adenocarcinomas. Cancer Res. 2007;67(2):836–43.PubMedCrossRef Canene-Adams K, Lindshield BL, Wang S, Jeffery EH, Clinton SK, Erdman JW Jr. Combinations of tomato and broccoli enhance antitumor activity in Dunning R3327-H prostate adenocarcinomas. Cancer Res. 2007;67(2):836–43.PubMedCrossRef
18.
go back to reference Applegate C, Rowles J 3rd, Miller R, Wallig M, Clinton S, O’Brien W et al. Dietary Tomato, but Not Lycopene Supplementation, Impacts Molecular Outcomes of Castration-resistant Prostate Cancer in the TRAMP Model. Curr Dev Nutr. 2019;3(Suppl1):eCollection https://doi.org/10.1093/cdn/nzz030.P05-015-19. Applegate C, Rowles J 3rd, Miller R, Wallig M, Clinton S, O’Brien W et al. Dietary Tomato, but Not Lycopene Supplementation, Impacts Molecular Outcomes of Castration-resistant Prostate Cancer in the TRAMP Model. Curr Dev Nutr. 2019;3(Suppl1):eCollection https://​doi.​org/​10.​1093/​cdn/​nzz030.​P05-015-19.
19.
go back to reference Mossine VV, Chopra P, Mawhinney TP. Interaction of tomato lycopene and ketosamine against rat prostate tumorigenesis. Cancer Res. 2008;68(11):4384–91.PubMedCrossRef Mossine VV, Chopra P, Mawhinney TP. Interaction of tomato lycopene and ketosamine against rat prostate tumorigenesis. Cancer Res. 2008;68(11):4384–91.PubMedCrossRef
20.
go back to reference Cellini A, Natali PG, Iezzi M, Piantelli M, Fogliano V, Iacobelli S. Efficacy and safety of Lycoprozen®, a novel tomato-based food supplement in patients with benign prostatic hyperplasia. Int J Nutr. 2018;3(2):1–5.CrossRef Cellini A, Natali PG, Iezzi M, Piantelli M, Fogliano V, Iacobelli S. Efficacy and safety of Lycoprozen®, a novel tomato-based food supplement in patients with benign prostatic hyperplasia. Int J Nutr. 2018;3(2):1–5.CrossRef
21.
go back to reference Fogliano V, Iacobelli S, Piantelli M. “Tomato powder-based composition”. 2016; US Patent App. 15/024,165. Fogliano V, Iacobelli S, Piantelli M. “Tomato powder-based composition”. 2016; US Patent App. 15/024,165.
22.
go back to reference Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol. 1997;157(4):1301–3.PubMedCrossRef Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol. 1997;157(4):1301–3.PubMedCrossRef
23.
go back to reference Badia X, Garcia-Losa M, Dal-Re R. Ten-language translation and harmonization of the International prostate symptom score: developing methodology for multinational clinical trials. Eur Urol. 1997;31(2):129–40.PubMedCrossRef Badia X, Garcia-Losa M, Dal-Re R. Ten-language translation and harmonization of the International prostate symptom score: developing methodology for multinational clinical trials. Eur Urol. 1997;31(2):129–40.PubMedCrossRef
24.
go back to reference Luvizotto Rde A, Nascimento AF, Imaizumi E, Pierine DT, Conde SJ, Correa CR, et al. Lycopene supplementation modulates plasma concentrations and epididymal adipose tissue mRNA of leptin, resistin, and IL-6 in diet-induced obese rats. Brit J Nutr. 2013;110(10):1803–9.PubMedCrossRef Luvizotto Rde A, Nascimento AF, Imaizumi E, Pierine DT, Conde SJ, Correa CR, et al. Lycopene supplementation modulates plasma concentrations and epididymal adipose tissue mRNA of leptin, resistin, and IL-6 in diet-induced obese rats. Brit J Nutr. 2013;110(10):1803–9.PubMedCrossRef
25.
go back to reference Kim YI, Mohri S, Hirai S, Lin S, Goto T, Ohvane C, et al. Tomato extract suppresses the production of proinflammatory mediators induced by interaction between adipocytes and macrophages. Biosci Biotechnol Biochem. 2015;79(1):82–7.PubMedCrossRef Kim YI, Mohri S, Hirai S, Lin S, Goto T, Ohvane C, et al. Tomato extract suppresses the production of proinflammatory mediators induced by interaction between adipocytes and macrophages. Biosci Biotechnol Biochem. 2015;79(1):82–7.PubMedCrossRef
26.
go back to reference Cheng HM, Koutsidis G, Lodge JK, Ashor A, Siervo M, Lara J. Tomato and lycopene supplementation and cardiovascular risk factors: A systematic review and meta-analysis. Atherosclerosis. 2017;257:100–8.PubMedCrossRef Cheng HM, Koutsidis G, Lodge JK, Ashor A, Siervo M, Lara J. Tomato and lycopene supplementation and cardiovascular risk factors: A systematic review and meta-analysis. Atherosclerosis. 2017;257:100–8.PubMedCrossRef
28.
go back to reference Wertz K, Siler U, Goralczyk R. Lycopene: modes of action to promote prostate health. Arch Biochemical Biophys. 2004;430(1):127–34.CrossRef Wertz K, Siler U, Goralczyk R. Lycopene: modes of action to promote prostate health. Arch Biochemical Biophys. 2004;430(1):127–34.CrossRef
29.
go back to reference Kouka P, Chatzieffraimidi GA, Raftis G, Stagos D, Angelis A, Stathopoulos P, et al. Antioxidant effects of an olive oil total polyphenolic fraction from a Greek Olea europaea variety in different cell cultures. Phytomedicine. 2018;47:135–42.PubMedCrossRef Kouka P, Chatzieffraimidi GA, Raftis G, Stagos D, Angelis A, Stathopoulos P, et al. Antioxidant effects of an olive oil total polyphenolic fraction from a Greek Olea europaea variety in different cell cultures. Phytomedicine. 2018;47:135–42.PubMedCrossRef
30.
go back to reference Zhao Q, Yang F, Meng L, Chen D, Wang M, Lu X, et al. Lycopene attenuates chronic prostatitis/chronic pelvic pain syndrome by inhibiting oxidative stress and inflammation via the interaction of NF-kB, MAPKs, and Nrf2 signaling pathways in rats. Andrology. 2020;8(3):747–55.PubMedPubMedCentralCrossRef Zhao Q, Yang F, Meng L, Chen D, Wang M, Lu X, et al. Lycopene attenuates chronic prostatitis/chronic pelvic pain syndrome by inhibiting oxidative stress and inflammation via the interaction of NF-kB, MAPKs, and Nrf2 signaling pathways in rats. Andrology. 2020;8(3):747–55.PubMedPubMedCentralCrossRef
31.
go back to reference Fernández-Bedmar Z, Anter J, Alonso MÁ. Anti/genotoxic, longevity inductive, cytotoxic, and clastogenic-related bioactivities of tomato and lycopene. Environ Mol Mutagen. 2018;59(5):427–37.PubMedCrossRef Fernández-Bedmar Z, Anter J, Alonso MÁ. Anti/genotoxic, longevity inductive, cytotoxic, and clastogenic-related bioactivities of tomato and lycopene. Environ Mol Mutagen. 2018;59(5):427–37.PubMedCrossRef
32.
go back to reference .Roehrborn C. G., McConnell J. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In Walsh P, Retik A, Vaughan E, Wein A, editors. Campbell’s Urology 8th Edition. Philadelphia: Saunders; 2002. Pp. 1297–1333. .Roehrborn C. G., McConnell J. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In Walsh P, Retik A, Vaughan E, Wein A, editors. Campbell’s Urology 8th Edition. Philadelphia: Saunders; 2002. Pp. 1297–1333.
33.
go back to reference Umtergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age related tissue remodeling. Exp Gerontol. 2005;40(3):121–8.CrossRef Umtergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age related tissue remodeling. Exp Gerontol. 2005;40(3):121–8.CrossRef
34.
go back to reference Kim HS, Bowen P, Chen L, Duncan C, Ghosh L, Sharifi R, et al. Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutr Cancer. 2003;47(1):40–7.PubMedCrossRef Kim HS, Bowen P, Chen L, Duncan C, Ghosh L, Sharifi R, et al. Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutr Cancer. 2003;47(1):40–7.PubMedCrossRef
35.
go back to reference Liu C, Lian F, Smith DE, Russel RM, Wang X-D. Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res. 2003;63(12):3138–44.PubMed Liu C, Lian F, Smith DE, Russel RM, Wang X-D. Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res. 2003;63(12):3138–44.PubMed
37.
go back to reference Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol. 2000;37(4):404–12.PubMedCrossRef Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol. 2000;37(4):404–12.PubMedCrossRef
38.
go back to reference Meert T, Baten E, van Renterghem K. Clinical importance of histopathological inflammation in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: a prospective study of 222 patients. Curr Urol. 2017;10(3):150–3.PubMedPubMedCentralCrossRef Meert T, Baten E, van Renterghem K. Clinical importance of histopathological inflammation in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: a prospective study of 222 patients. Curr Urol. 2017;10(3):150–3.PubMedPubMedCentralCrossRef
39.
go back to reference Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, van Breemen R, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst. 2001;93(24):1872–9.PubMedCrossRef Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, van Breemen R, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst. 2001;93(24):1872–9.PubMedCrossRef
40.
go back to reference Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, et al. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology. 2007;69(2):289–94.PubMedCrossRef Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, et al. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology. 2007;69(2):289–94.PubMedCrossRef
41.
go back to reference Bunker CH, McDonald AC, Evans RW, de la Rosa N, Boumosleh JM, Patrick A. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutr Cancer. 2007;57(2):130–7.PubMedCrossRef Bunker CH, McDonald AC, Evans RW, de la Rosa N, Boumosleh JM, Patrick A. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutr Cancer. 2007;57(2):130–7.PubMedCrossRef
42.
go back to reference Paur I, Lilleby W, Kjølsrud Bøhn S, Hulande E, Klein W, Vlatkovic L, et al. Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA. Clin Nutr. 2017;36(3):672–9.PubMedCrossRef Paur I, Lilleby W, Kjølsrud Bøhn S, Hulande E, Klein W, Vlatkovic L, et al. Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA. Clin Nutr. 2017;36(3):672–9.PubMedCrossRef
45.
go back to reference Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratlift TL, Smith DS, et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate-specific antigen levels. J Urol. 1992;147(3pt2):810–4.PubMedCrossRef Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratlift TL, Smith DS, et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate-specific antigen levels. J Urol. 1992;147(3pt2):810–4.PubMedCrossRef
46.
go back to reference Ørsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3 009 258 men. Eur Urol. 2011;60(4):691–8.PubMedCrossRef Ørsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3 009 258 men. Eur Urol. 2011;60(4):691–8.PubMedCrossRef
47.
go back to reference Huang JG, Campbell N, Goldenberg SL. PSA and beyond: Biomarkers in prostate cancer. BC Med J. 2014;56(7):334–41. Huang JG, Campbell N, Goldenberg SL. PSA and beyond: Biomarkers in prostate cancer. BC Med J. 2014;56(7):334–41.
48.
go back to reference Morote J, Ravento CX, Lorente JA, Miguel A, Lopez-Pacios MA, Encabo G, et al. Measurement of free PSA in the diagnosis and staging of prostate cancer. Int J Cancer. 1997;71(5):756–9.PubMedCrossRef Morote J, Ravento CX, Lorente JA, Miguel A, Lopez-Pacios MA, Encabo G, et al. Measurement of free PSA in the diagnosis and staging of prostate cancer. Int J Cancer. 1997;71(5):756–9.PubMedCrossRef
49.
go back to reference Walz J, Haese A, Scattoni V, Steuber T, Chun FKH, Briganti A, et al. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. Cancer. 2008;113(10):2695–703.PubMedCrossRef Walz J, Haese A, Scattoni V, Steuber T, Chun FKH, Briganti A, et al. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. Cancer. 2008;113(10):2695–703.PubMedCrossRef
50.
go back to reference Salehi B, Sharifi-Rad R, Sharopov F, Namiesnik J, Roointan A, Kamle M, et al. Beneficial effects and potential risks of tomato consumption for human health: an overview. Nutrition. 2019;62:201–8.PubMedCrossRef Salehi B, Sharifi-Rad R, Sharopov F, Namiesnik J, Roointan A, Kamle M, et al. Beneficial effects and potential risks of tomato consumption for human health: an overview. Nutrition. 2019;62:201–8.PubMedCrossRef
51.
go back to reference Chen P, Zhang W, Wang X, Zhao K, Singh Negi D, Zhuo L, et al. Lycopene and risk of prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(33):e1260.CrossRef Chen P, Zhang W, Wang X, Zhao K, Singh Negi D, Zhuo L, et al. Lycopene and risk of prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(33):e1260.CrossRef
52.
go back to reference Er V, Lane JA, Martin RM, Emmet P, Gilbert R, Avery KN, et al. Adherence to dietary and lifestyle recommendations and prostate cancer risk in the prostate testing for cancer and treatment (ProtecT) Trial. Cancer Epidemiol Biomarkers Prev. 2014;23(10):2066–77.PubMedPubMedCentralCrossRef Er V, Lane JA, Martin RM, Emmet P, Gilbert R, Avery KN, et al. Adherence to dietary and lifestyle recommendations and prostate cancer risk in the prostate testing for cancer and treatment (ProtecT) Trial. Cancer Epidemiol Biomarkers Prev. 2014;23(10):2066–77.PubMedPubMedCentralCrossRef
54.
go back to reference Han GM, Meza JL, Soliman GA, Islam KM, Aatanabe-Galloway S. Higher levels of serum lycopene are associated with reduced mortality in individuals with metabolic syndrome. Nutr Res. 2016;36(5):402–7.PubMedCrossRef Han GM, Meza JL, Soliman GA, Islam KM, Aatanabe-Galloway S. Higher levels of serum lycopene are associated with reduced mortality in individuals with metabolic syndrome. Nutr Res. 2016;36(5):402–7.PubMedCrossRef
55.
go back to reference Li Y, Wang H, Zhang Y, Martin C. Can the world’s favorite fruit, tomato, provide a biosynthetic chassis for high-value metabolites? Plant Cell Rep. 2018;37(10):1443–50.PubMedPubMedCentralCrossRef Li Y, Wang H, Zhang Y, Martin C. Can the world’s favorite fruit, tomato, provide a biosynthetic chassis for high-value metabolites? Plant Cell Rep. 2018;37(10):1443–50.PubMedPubMedCentralCrossRef
Metadata
Title
Improvement of urinary tract symptoms and quality of life in benign prostate hyperplasia patients associated with consumption of a newly developed whole tomato-based food supplement: a phase II prospective, randomized double-blinded, placebo-controlled study
Authors
Luigi Cormio
Beppe Calò
Ugo Falagario
Manuela Iezzi
Alessia Lamolinara
Paola Vitaglione
Giovanni Silecchia
Giuseppe Carrieri
Vincenzo Fogliano
Stefano Iacobelli
Pier Giorgio Natali
Mauro Piantelli
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-020-02684-3

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.